Unicycive Therapeutics (NASDAQ:UNCY) Downgraded to Sell Rating by Wall Street Zen
by Renee Jackson · The Cerbat GemWall Street Zen lowered shares of Unicycive Therapeutics (NASDAQ:UNCY – Free Report) from a hold rating to a sell rating in a report released on Saturday morning.
A number of other equities analysts have also recently issued reports on the stock. Westpark Capital initiated coverage on shares of Unicycive Therapeutics in a research report on Thursday, February 19th. They set a “buy” rating for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Unicycive Therapeutics in a research report on Friday, March 27th. B. Riley Financial initiated coverage on shares of Unicycive Therapeutics in a research report on Friday. They set a “buy” rating and a $22.00 target price for the company. Guggenheim cut their target price on shares of Unicycive Therapeutics from $46.00 to $40.00 and set a “buy” rating for the company in a research report on Thursday, April 2nd. Finally, Benchmark cut their target price on shares of Unicycive Therapeutics from $21.00 to $15.00 and set a “speculative buy” rating for the company in a research report on Monday, April 6th. Five research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $24.75.
Check Out Our Latest Stock Report on UNCY
Unicycive Therapeutics Stock Up 0.1%
Shares of NASDAQ UNCY opened at $7.67 on Friday. Unicycive Therapeutics has a 52 week low of $3.71 and a 52 week high of $11.00. The firm has a 50-day moving average price of $6.88 and a 200 day moving average price of $6.19. The stock has a market capitalization of $193.59 million, a price-to-earnings ratio of -3.53 and a beta of 1.78.
Unicycive Therapeutics (NASDAQ:UNCY – Get Free Report) last announced its quarterly earnings data on Monday, March 30th. The company reported ($0.82) EPS for the quarter, missing the consensus estimate of ($0.46) by ($0.36). Equities research analysts expect that Unicycive Therapeutics will post 1.12 EPS for the current fiscal year.
Hedge Funds Weigh In On Unicycive Therapeutics
A number of institutional investors have recently modified their holdings of the company. Vivo Capital LLC raised its position in shares of Unicycive Therapeutics by 57.4% in the third quarter. Vivo Capital LLC now owns 1,789,916 shares of the company’s stock valued at $7,804,000 after buying an additional 652,901 shares during the last quarter. Millennium Management LLC acquired a new position in shares of Unicycive Therapeutics in the fourth quarter valued at approximately $5,856,000. Vanguard Group Inc. raised its position in shares of Unicycive Therapeutics by 8.7% in the third quarter. Vanguard Group Inc. now owns 658,878 shares of the company’s stock valued at $2,873,000 after buying an additional 52,925 shares during the last quarter. Cantor Fitzgerald L. P. acquired a new position in shares of Unicycive Therapeutics in the fourth quarter valued at approximately $1,154,000. Finally, Geode Capital Management LLC raised its position in shares of Unicycive Therapeutics by 36.2% in the fourth quarter. Geode Capital Management LLC now owns 171,290 shares of the company’s stock valued at $989,000 after buying an additional 45,563 shares during the last quarter. Institutional investors and hedge funds own 40.42% of the company’s stock.
Unicycive Therapeutics Company Profile
Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.